TerraPower Isotopes Invests $450M in Actinium-225 Production Facility

oncodaily - TerraPower Isotopes (TPI), the Bill Gates-founded nuclear science company, unveiled plans on March 17, 2026 to invest $450 million in a state-of-the-art actinium-225 (Ac-225) manufacturing facility in Philadelphia’s Bellwether District. The 250,000-square…

AI Summary: TerraPower announced a $450 million investment to construct a commercial Actinium‑225 production facility to supply alpha‑emitting radioisotopes for targeted cancer therapies. The plan tackles chronic supply shortages, strengthens domestic radiopharmaceutical capacity and positions the company at the center of growing demand for targeted‑alpha therapeutics — and yes, investors are watching.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Cancer Grand Challenges awards five teams bold funding for cancer research / 2 months

Oricell raises tens of millions to expand CAR‑T efforts / 7 wks

Bristol Myers and Hengrui strike up to $15.2B global oncology pact / 16 days

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival / 2 months

HORMAD1 emerges as a potential target in triple‑negative breast cancer / 2 months

Roche’s hoped‑for breast cancer pill fails crucial first‑line trial / 2 months

Romiplostim prevents chemo-induced platelet crashes in phase 3 trial / 2 months